Fumitaka Suto

461 total citations
19 papers, 236 citations indexed

About

Fumitaka Suto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Fumitaka Suto has authored 19 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Fumitaka Suto's work include HER2/EGFR in Cancer Research (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Advanced Breast Cancer Therapies (5 papers). Fumitaka Suto is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Advanced Breast Cancer Therapies (5 papers). Fumitaka Suto collaborates with scholars based in Japan, United States and United Kingdom. Fumitaka Suto's co-authors include Yusuke Kuwahara, Tomohiro Nishina, Kazuhito Kawabata, Hisato Kawakami, Kensei Yamaguchi, Cheryl L. Rowe-Rendleman, Satoshi Nakayama, Koichiro Inaki, Yasushi Hirota and Valentina Boni and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Fumitaka Suto

19 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fumitaka Suto Japan 10 124 67 60 37 36 19 236
Marta Valeri Spain 9 38 0.3× 43 0.6× 27 0.5× 122 3.3× 153 4.3× 11 345
Tyler M. Hudish United States 8 79 0.6× 29 0.4× 53 0.9× 79 2.1× 155 4.3× 8 343
Jiyoung Yu South Korea 10 26 0.2× 32 0.5× 39 0.7× 31 0.8× 185 5.1× 25 332
Elena Perrino Italy 7 94 0.8× 89 1.3× 11 0.2× 11 0.3× 105 2.9× 8 345
Iain MacEwan United States 7 45 0.4× 27 0.4× 41 0.7× 4 0.1× 125 3.5× 16 354
Antonietta Pia Gallo Italy 10 74 0.6× 7 0.1× 30 0.5× 42 1.1× 219 6.1× 12 343
Stefanie de Groot Netherlands 7 76 0.6× 26 0.4× 29 0.5× 2 0.1× 101 2.8× 12 370
Allyson L. Toro United States 13 23 0.2× 16 0.2× 12 0.2× 95 2.6× 235 6.5× 29 355
Yangyang Li China 8 27 0.2× 72 1.1× 41 0.7× 7 0.2× 91 2.5× 28 261
Jianxin Yang United States 7 61 0.5× 39 0.6× 8 0.1× 5 0.1× 206 5.7× 8 323

Countries citing papers authored by Fumitaka Suto

Since Specialization
Citations

This map shows the geographic impact of Fumitaka Suto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumitaka Suto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumitaka Suto more than expected).

Fields of papers citing papers by Fumitaka Suto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumitaka Suto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumitaka Suto. The network helps show where Fumitaka Suto may publish in the future.

Co-authorship network of co-authors of Fumitaka Suto

This figure shows the co-authorship network connecting the top 25 collaborators of Fumitaka Suto. A scholar is included among the top collaborators of Fumitaka Suto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumitaka Suto. Fumitaka Suto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Pistilli, Barbara, Luisa Pierotti, Cécile Vicier, et al.. (2024). 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Annals of Oncology. 35. S357–S357. 11 indexed citations
2.
Brieu, Nicolas, Anatoliy Shumilov, Armin Meier, et al.. (2024). HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Scientific Reports. 14(1). 12129–12129. 16 indexed citations
3.
Siena, Salvatore, Kanwal Raghav, Toshiki Masuishi, et al.. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. 15(1). 10213–10213. 15 indexed citations
4.
5.
Koyama, Shohei, Fumitaka Suto, Takeo Arita, et al.. (2024). The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer. Cancer Research Communications. 5(1). 84–93. 1 indexed citations
6.
Failmezger, Henrik, Jessica Chan, Anatoliy Shumilov, et al.. (2023). Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).. Journal of Clinical Oncology. 41(4_suppl). 449–449. 1 indexed citations
7.
8.
9.
10.
11.
12.
Modi, Shanu, Fabrice André, Ian E. Krop, et al.. (2020). Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.. Journal of Clinical Oncology. 38(15_suppl). 1036–1036. 16 indexed citations
13.
Frankle, W. Gordon, Rajesh Narendran, Fumitaka Suto, et al.. (2017). Brain translocator protein occupancy by ONO‐2952 in healthy adults: A Phase 1 PET study using [11C]PBR28. Synapse. 71(7). 7 indexed citations
14.
15.
Suto, Fumitaka, et al.. (2015). Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers. Clinical Therapeutics. 37(9). 2071–2084. 8 indexed citations
16.
Suto, Fumitaka, et al.. (2015). A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. Investigative Ophthalmology & Visual Science. 56(13). 7963–7963. 16 indexed citations
17.
Nakayama, Satoshi, et al.. (2015). IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Investigative Ophthalmology & Visual Science. 56(4). 2547–2547. 31 indexed citations
18.
Matsumoto, Ichiro, et al.. (2009). In Vitro Metabolism and Inhibitory Effects of Pranlukast in Human Liver Microsomes. Biological and Pharmaceutical Bulletin. 32(4). 688–693. 9 indexed citations
19.
Takagi, Mitsuhiro, Fumitaka Suto, Tetsuya Suga, & Junji Yamada. (2005). Sterol Regulatory Element-Binding Protein-2 modulates human brain acyl-CoA hydrolase gene transcription. Molecular and Cellular Biochemistry. 275(1-2). 199–206. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Valeri Breakdown of academic impact, for papers by Tyler M. Hudish Breakdown of academic impact, for papers by Jiyoung Yu Breakdown of academic impact, for papers by Elena Perrino Breakdown of academic impact, for papers by Iain MacEwan Breakdown of academic impact, for papers by Antonietta Pia Gallo Breakdown of academic impact, for papers by Stefanie de Groot Breakdown of academic impact, for papers by Allyson L. Toro Breakdown of academic impact, for papers by Yangyang Li Breakdown of academic impact, for papers by Jianxin Yang
Rankless by CCL
2026